基本信息
浏览量:61
职业迁徙
个人简介
Research interests: Immunology, immunotherapy, molecular medicine
Özlem Türeci is a physician and basic researcher in the field of immunology. She researches target structures with a view to developing new treatments for cancer, infectious diseases and diseases of the immune and nervous systems. Together with Uğur Şahin, with whom she co-founded the biotechnology company BioNTech, she developed the mRNA vaccine Comirnaty against COVID-19, and in doing so became one of the leading figures in the fight against the pandemic.
Over the last 20 years, Özlem Türeci and Uğur Şahin have solved several of the challenges associated with mRNA vaccines. They have developed methods for delivering mRNA to dendritic cells using a suitable lipid carrier; improved the stability of the mRNA; and increased the level of protein transfer by 1000 times.
In addition to developing diagnostics and monoclonal antibodies – including zolbetuximab, an antibody that targets gastric and oesophageal cancer – Özlem Türeci has also focussed her research efforts on mRNA-based immunotherapy. This area of her work looks at developing targeted cancer medications as well as immunotherapeutic vaccines against diseases such as tuberculosis and HIV. Since co-founding both Ganymed Pharmaceuticals and BioNTech, she has worked on numerous projects in the fields of oncology and vaccines and is co-inventor of more than 500 patents. During the development of BioNTech's COVID-19 vaccine BNT162b2 (brand name Comirnaty), she was responsible for organising the clinical trials. She and Uğur Şahin have since received numerous prizes from around the world in recognition of their achievement.
Özlem Türeci is a physician and basic researcher in the field of immunology. She researches target structures with a view to developing new treatments for cancer, infectious diseases and diseases of the immune and nervous systems. Together with Uğur Şahin, with whom she co-founded the biotechnology company BioNTech, she developed the mRNA vaccine Comirnaty against COVID-19, and in doing so became one of the leading figures in the fight against the pandemic.
Over the last 20 years, Özlem Türeci and Uğur Şahin have solved several of the challenges associated with mRNA vaccines. They have developed methods for delivering mRNA to dendritic cells using a suitable lipid carrier; improved the stability of the mRNA; and increased the level of protein transfer by 1000 times.
In addition to developing diagnostics and monoclonal antibodies – including zolbetuximab, an antibody that targets gastric and oesophageal cancer – Özlem Türeci has also focussed her research efforts on mRNA-based immunotherapy. This area of her work looks at developing targeted cancer medications as well as immunotherapeutic vaccines against diseases such as tuberculosis and HIV. Since co-founding both Ganymed Pharmaceuticals and BioNTech, she has worked on numerous projects in the fields of oncology and vaccines and is co-inventor of more than 500 patents. During the development of BioNTech's COVID-19 vaccine BNT162b2 (brand name Comirnaty), she was responsible for organising the clinical trials. She and Uğur Şahin have since received numerous prizes from around the world in recognition of their achievement.
研究兴趣
论文共 342 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Timothy E. Albertson, Caitlin Hansen, Smiti Bihari, Juleen Gayed,Xia Xu, J. Abraham Simón-Campos, Michael E. Dever,Jose F. Cardona,Essack Mitha, Jeffrey B. Baker, Georgina Keep, Islamiat Oladipupo,
Nature Reviews Drug Discoveryno. 2 (2024): 156-156
Jan D. Beck,Mustafa Diken,Martin Suchan, Michael Streuber,Elif Diken, Laura Kolb, Lisa Allnoch,Fulvia Vascotto, Daniel Peters,Tim Beißert,Özlem Akilli-Öztürk,Özlem Türeci,
Cancer Cellno. 4 (2024): 568-582.e11
Adam Zuiani, Charles L. Dulberger, Nilushi S. De Silva, Meghan Marquette, Yu-Jung Lu, Gavin M. Palowitch, Anja Dokic,Ricardo Sanchez-Velazquez, Katja Schlatterer, Sanjay Sarkar,Swagata Kar, Bhavna Chawla,
CELLno. 6 (2024): 1363-1373.e12
Juleen Gayed, Oyeniyi Diya, Francine S Lowry, Xia Xu, Vishva Bangad, Federico Mensa,Jing Zou,Xuping Xie,Yanping Hu,Claire Lu,Mark Cutler,Todd Belanger,
Vaccinesno. 2 (2024): 118
Juleen Gayed, Vishva Bangad,Xia Xu, Federico Mensa,Mark Cutler,Özlem Türeci,Uǧur Şahin,Kayvon Modjarrad,Kena A. Swanson,Annaliesa S. Anderson,Alejandra Gurtman,Nicholas Kitchin
crossref(2024)
Toshihide Nishibata, Jane Weng, Keisuke Omori, Yuji Sato,Taisuke Nakazawa,Tomoyuki Suzuki, Tomohiro Yamada,Ikumi Nakajo,Fumitaka Kinugasa,Özlem Türeci,Uğur Şahin,Taku Yoshida
Journal of Pharmacological Sciencesno. 3 (2024): 84-93
Christiane R Stadler,Ursula Ellinghaus, Leyla Fischer, Hayat Bähr-Mahmud, Martin Rao,Claudia Lindemann, Anuhar Chaturvedi, Caroline Scharf, Imke Biermann, Bernhard Hebich, Alexandra Malz, Georg Beresin,
Science translational medicineno. 748 (2024): eadl2720-eadl2720
Juleen Gayed, Oyeniyi Diya, Francine S. Lowry,Xia Xu, Vishva Bangad, Federico Mensa,Jing Zou,Xuping Xie,Yanping Hu,Claire Lu,Mark Cutler,Todd Belanger,
VACCINESno. 2 (2024)
Bala Başak Öven, David Vicente Baz, Jürgen Wolf, Ozturk Ates,Erdem Göker, Patrick Brück, Michael Wenger, Neru Munshi, Iryna Tsyhankova, Iryna Tsyhankova, Malgorzata Kaczorowska, Thomas Schell,
Cancer Researchno. 7_Supplement (2024)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn